glp-1 microdose Microdosing Drugs: What To Know EllieMD | Microdose - EllieMD
Description
Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks
Ongoing Trials: EVOKE a phase 3 randomized double-blinded study of 14 mg daily semaglutide in patients aged 5085 years with mild dementia
But most GLP-1 users do not live inside a curve
Retatrutides manufacturers are studying the drugs effects on weight loss and knee pain from osteoarthritis, and early results indicate positive effects
Journal of Orthopaedic Translation
Accessed February 17, 2026
